Cargando…
Sclerostin Inhibition in the Management of Osteoporosis
The recognition of the importance of the Wnt-signaling pathway in bone metabolism and studies of patients with rare skeletal disorders characterized by high bone mass identified sclerostin as target for the development of new therapeutics for osteoporosis. Findings in animals and humans with scleros...
Autores principales: | Appelman-Dijkstra, Natasha M., Papapoulos, Socrates E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824823/ https://www.ncbi.nlm.nih.gov/pubmed/27016922 http://dx.doi.org/10.1007/s00223-016-0126-6 |
Ejemplares similares
-
From disease to treatment: from rare skeletal disorders to treatments for osteoporosis
por: Appelman-Dijkstra, Natasha M., et al.
Publicado: (2016) -
Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis
por: Appelman-Dijkstra, Natasha M., et al.
Publicado: (2015) -
Combination and sequential treatments in the management of osteoporosis
por: Papapoulos, Socrates
Publicado: (2012) -
Serum sclerostin levels in osteoporotic fracture patients
por: Gorter, Erwin A., et al.
Publicado: (2022) -
Sclerostin: Current Knowledge and Future Perspectives
por: Moester, M. J. C., et al.
Publicado: (2010)